Zogenix Announces Acquisition of Modis Therapeutics, Inc.
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Advances Zogenix?s strategy to provide transformative therapies to patients and families living with serious rare diseases
- Adds MT1621, a proprietary, late-stage investigational medicine targeting Thymidine Kinase 2 deficiency (TK2d) that has received FDA Breakthrough Therapy and?EMA PRIME?designations
- Investor conference call and webcast today at?8:30 AM ET
Conference Call Details | |
8:30 AM Eastern Time / 5:30 AM Pacific Time | |
Toll Free: | 1-877-407-9716 |
International: | 1-201-493-6779 |
Conference ID: | 13694139 |
Webcast (with slides): | http://public.viavid.com/index.php?id=135987 |